RS
RXRX icon

R Squared’s Recursion Pharmaceuticals RXRX Stock Holding History

R Squared’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$99.4K Buy
32,363
+11,118
+52% +$43K 0.05% 367
2025
Q4 		$86.9K Sell
21,245
-14,151
-40% -$70.1K 0.04% 425
2025
Q3 		$173K Sell
35,396
-25,861
-42% -$136K 0.07% 401
2025
Q2 		$310K Buy
61,257
+47,577
+348% +$234K 0.17% 210
2025
Q1 		$72.4K Buy
+13,680
New +$99.7K 0.08% 240

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

R Squared's RXRX Position: Q1 2026 in Review

R Squared increased its Recursion Pharmaceuticals (RXRX) stake by 52% in Q1 2026, buying an estimated $43K and bringing the position to 32,363 shares worth $99.4K. The position accounts for 0.05% of the portfolio, ranked #367.

R Squared first reported a position in RXRX in Q1 2025 and has held it in 5 quarters since. The position peaked at $310K in Q2 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • R Squared held 32,363 shares of Recursion Pharmaceuticals worth $99.4K as of Q1 2026.
  • R Squared bought 11,118 Recursion Pharmaceuticals shares in Q1 2026, an estimated $43K.
  • Recursion Pharmaceuticals made up 0.05% of R Squared's portfolio in Q1 2026, its #367 holding.
  • R Squared first reported a position in Recursion Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • R Squared's Recursion Pharmaceuticals position peaked at $310K in Q2 2025.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on R Squared's 13F filing for Q1 2026, filed 29 Apr 2026.